Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent advances in non-peptidic RANTES antagonists.

F Halley1

  • 1Rhône-Poulenc Rorer, Dagenham Research Centre, Dagenham, Essex, RM10 7XS, UK. frank.halley@rp-rorer.co.uk

Idrugs : the Investigational Drugs Journal
|September 24, 2005
PubMed
Summary

Chemokines like RANTES regulate immune cell movement and inflammation. This review covers non-peptidic RANTES antagonists, which are emerging as new therapeutic options for various diseases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Blood culture collection].

Deutsche medizinische Wochenschrift (1946)·2010
Same author

Potential of p38 inhibitors in the treatment of rheumatoid arthritis.

Drug news & perspectives·2003
Same author

RPR203494 a pyrimidine analogue of the p38 inhibitor RPR200765A with an improved in vitro potency.

Bioorganic & medicinal chemistry letters·2001
Same author

The discovery of RPR 200765A, a p38 MAP kinase inhibitor displaying a good oral anti-arthritic efficacy.

Bioorganic & medicinal chemistry·2001
Same author

Selective ET(A) antagonists. 5. Discovery and structure-activity relationships of phenoxyphenylacetic acid derivatives.

Journal of medicinal chemistry·2000
Same author

Identification of a non peptidic RANTES antagonist.

Bioorganic & medicinal chemistry letters·1999

Area of Science:

  • Immunology
  • Molecular Biology

Background:

  • RANTES (Regulated on Activation, Normal T Cell Expressed and Secreted) is a chemokine.
  • Chemokines orchestrate leukocyte recruitment and inflammatory responses.
  • RANTES's role in disease pathogenesis is established, with antibody and peptide inhibitors showing efficacy.

Purpose of the Study:

  • To review the emerging field of non-peptidic RANTES antagonists.
  • To highlight their potential therapeutic applications.

Main Methods:

  • Literature review of recent publications on RANTES antagonists.
  • Analysis of chemical structures and biological activities of non-peptidic antagonists.

Main Results:

  • Identification and characterization of various non-peptidic RANTES antagonist scaffolds.
  • Discussion of their mechanisms of action and potential advantages over peptide-based inhibitors.

Conclusions:

  • Non-peptidic RANTES antagonists represent a promising new class of therapeutics.
  • Further research is warranted to develop these antagonists for clinical use in inflammatory diseases.

Related Experiment Videos